These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 15102698)

  • 1. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity.
    Yang SC; Hillinger S; Riedl K; Zhang L; Zhu L; Huang M; Atianzar K; Kuo BY; Gardner B; Batra RK; Strieter RM; Dubinett SM; Sharma S
    Clin Cancer Res; 2004 Apr; 10(8):2891-901. PubMed ID: 15102698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma.
    Yang SC; Batra RK; Hillinger S; Reckamp KL; Strieter RM; Dubinett SM; Sharma S
    Cancer Res; 2006 Mar; 66(6):3205-13. PubMed ID: 16540672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo.
    Sharma S; Stolina M; Luo J; Strieter RM; Burdick M; Zhu LX; Batra RK; Dubinett SM
    J Immunol; 2000 May; 164(9):4558-63. PubMed ID: 10779757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-gamma-dependent antitumor responses in a lung cancer model.
    Hillinger S; Yang SC; Zhu L; Huang M; Duckett R; Atianzar K; Batra RK; Strieter RM; Dubinett SM; Sharma S
    J Immunol; 2003 Dec; 171(12):6457-65. PubMed ID: 14662845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma.
    Sharma S; Stolina M; Zhu L; Lin Y; Batra R; Huang M; Strieter R; Dubinett SM
    Cancer Res; 2001 Sep; 61(17):6406-12. PubMed ID: 11522634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer.
    Baratelli F; Takedatsu H; Hazra S; Peebles K; Luo J; Kurimoto PS; Zeng G; Batra RK; Sharma S; Dubinett SM; Lee JM
    J Transl Med; 2008 Jul; 6():38. PubMed ID: 18644162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response.
    Flanagan K; Glover RT; Hörig H; Yang W; Kaufman HL
    Vaccine; 2004 Jul; 22(21-22):2894-903. PubMed ID: 15246626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10.
    Sharma S; Yang SC; Hillinger S; Zhu LX; Huang M; Batra RK; Lin JF; Burdick MD; Strieter RM; Dubinett SM
    Mol Cancer; 2003 Apr; 2():22. PubMed ID: 12740040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication.
    Miller PW; Sharma S; Stolina M; Butterfield LH; Luo J; Lin Y; Dohadwala M; Batra RK; Wu L; Economou JS; Dubinett SM
    Hum Gene Ther; 2000 Jan; 11(1):53-65. PubMed ID: 10646639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells.
    Matsuyoshi H; Hirata S; Yoshitake Y; Motomura Y; Fukuma D; Kurisaki A; Nakatsura T; Nishimura Y; Senju S
    Cancer Sci; 2005 Dec; 96(12):889-96. PubMed ID: 16367909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I Trial of Intratumoral Injection of
    Lee JM; Lee MH; Garon E; Goldman JW; Salehi-Rad R; Baratelli FE; Schaue D; Wang G; Rosen F; Yanagawa J; Walser TC; Lin Y; Park SJ; Adams S; Marincola FM; Tumeh PC; Abtin F; Suh R; Reckamp KL; Lee G; Wallace WD; Lee S; Zeng G; Elashoff DA; Sharma S; Dubinett SM
    Clin Cancer Res; 2017 Aug; 23(16):4556-4568. PubMed ID: 28468947
    [No Abstract]   [Full Text] [Related]  

  • 13. Enhanced priming of antigen-specific CTLs in vivo by embryonic stem cell-derived dendritic cells expressing chemokine along with antigenic protein: application to antitumor vaccination.
    Matsuyoshi H; Senju S; Hirata S; Yoshitake Y; Uemura Y; Nishimura Y
    J Immunol; 2004 Jan; 172(2):776-86. PubMed ID: 14707047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemokine gene modification of human dendritic cell-based tumor vaccines using a recombinant adenoviral vector.
    Terando A; Roessler B; Mulé JJ
    Cancer Gene Ther; 2004 Mar; 11(3):165-73. PubMed ID: 14726959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic antitumor effect by coexpression of chemokine CCL21/SLC and costimulatory molecule LIGHT.
    Hisada M; Yoshimoto T; Kamiya S; Magami Y; Miyaji H; Yoneto T; Tamada K; Aoki T; Koyanagi Y; Mizuguchi J
    Cancer Gene Ther; 2004 Apr; 11(4):280-8. PubMed ID: 15002032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of CCL-21/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cells.
    Riedl K; Baratelli F; Batra RK; Yang SC; Luo J; Escuadro B; Figlin R; Strieter R; Sharma S; Dubinett S
    Mol Cancer; 2003 Nov; 2():35. PubMed ID: 14613584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity.
    Tolba KA; Bowers WJ; Muller J; Housekneckt V; Giuliano RE; Federoff HJ; Rosenblatt JD
    Cancer Res; 2002 Nov; 62(22):6545-51. PubMed ID: 12438249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy.
    Kirk CJ; Hartigan-O'Connor D; Nickoloff BJ; Chamberlain JS; Giedlin M; Aukerman L; Mule JJ
    Cancer Res; 2001 Mar; 61(5):2062-70. PubMed ID: 11280767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors.
    Nukiwa M; Andarini S; Zaini J; Xin H; Kanehira M; Suzuki T; Fukuhara T; Mizuguchi H; Hayakawa T; Saijo Y; Nukiwa T; Kikuchi T
    Eur J Immunol; 2006 Apr; 36(4):1019-27. PubMed ID: 16525992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fractalkine transgene induces T-cell-dependent antitumor immunity through chemoattraction and activation of dendritic cells.
    Guo J; Zhang M; Wang B; Yuan Z; Guo Z; Chen T; Yu Y; Qin Z; Cao X
    Int J Cancer; 2003 Jan; 103(2):212-20. PubMed ID: 12455035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.